Gilead Looks Away From Hepatitis C Treatments for Growth

Gilead Sciences Inc.’s earnings fell less than expected in the most recent quarter as declining drug sales were partially offset by cost cuts, but executives warned the worst is yet to come for its hepatitis C treatments, which saw a 33% sales decline during the period.

Popular Posts


(Visited 2 times, 1 visits today)

Vote on this story -->>>

this is a single

THE MIAMI METROPOLIS -your source for news, music, sports, movies, restaurants, reviews, weather, travel, arts, tech and events in Miami